NEW YORK (GenomeWeb) – Meridian Bioscience today announced it has obtained CE marking for two molecular assays for detecting herpes simplex virus type 1 and type 2.
The company has launched the assays in Europe. They run on Meridian Bio's Illumigene platform and use cutaneous and mucocutaneous specimens from symptomatic patients for the qualitative detection and differentiation of HSV-1 and HSV-2 with results generated within one hour.
The Illumigene platform now supports nine molecular assays, Mike Shaughnessy, executive vice president and president of Meridian Global Diagnostics, said in a statement. In February, the company's molecular tests for Chlamydia trachomatis and Neisseria gonorrhoeae received CE marking.
"Coupled with our chlamydia and gonorrhea assays launched earlier this year, Meridian is now able to offer a compelling STD and women's health portfolio that will empower laboratories to test in house while using best-in-practice diagnostic methods for both infections," Shaughnessy said.